CR2O   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Amsterdam Netherlands (2008)

Organization Overview

First Clinical Trial
2017
NCT02888756
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CR2O | CR2O B.V.

Active Ingredients

Drugs in Phase 3 Trials (2)

galactooligosaccharide (1 trial)

maltodextrin (1 trial)

Drugs in Phase 2 Trials (5)

alprostadil (prostin) (1 trial)

ihivarna (1 trial)

papaverine (1 trial)

phentolamine mesylate (regitine) (1 trial)

trimix (1 trial)

Drugs in Phase 1 Trials (1)

mva-mers-s_df1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 1)

HIV Infections (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 8